Neoadjuvant chemotherapy with or without oxaliplatin after short-course radiotherapy in high-risk rectal cancer: A subgroup analysis from a prospective study.

ABSTRACT:

Aim

To evaluate the role of oxaliplatin in neoadjuvant chemotherapy delivered after short-course irradiation.

Background

Using oxaliplatin in the above setting is uncertain.

Patients and methods

A subgroup of 136 patients managed by short-course radiotherapy and 3 cycles of consolidation chemotherapy within the framework of a randomised study was included in this post-hoc analysis. Sixty-seven patients received FOLFOX4 (oxaliplatin group) while oxaliplatin was omitted in the second period of accrual in 69 patients because of protocol amendment (fluorouracil-only group).

Results

Grade 3+ acute toxicity from neoadjuvant treatment was observed in 30% of patients in the oxaliplatin group vs. 16% in the fluorouracil-only group (p = 0.053). The corresponding p

SUBMITTER: Kosakowska E 

PROVIDER: S-EPMC7772602 | biostudies-literature | 2020 Nov-Dec

REPOSITORIES: biostudies-literature